Compare Eli Lilly And Co (LLY) vs Petróleo Brasileiro SA (PBR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Petróleo Brasileiro SA — how do they compare? Eli Lilly And Co trades at $1,175.95 (market cap $1.04T), while Petróleo Brasileiro SA trades at $25.13 (market cap $151.94B). The key difference: Eli Lilly And Co is far larger — about 6.8× Petróleo Brasileiro SA's market cap, and Petróleo Brasileiro SA pays the higher dividend (6.79%). Which is the better fit depends on your goals — on Pluang, investors hold Eli Lilly And Co for 93 Days and Petróleo Brasileiro SA for 25 Days on average.
| LLY | PBR | |
|---|---|---|
Market Cap | $1.04T | $151.94B |
Volume | 3,064,878 | 30,240,092 |
Sector | Health | Energy |
52-Week High | $1.28K | $24.69 |
52-Week Low | $799.57 | $11.54 |
Typical Hold Time | 93 Days | 25 Days |
Enterprise Value | $1.09T | $212.36B |
Dividend Yield | 0.59% | 6.79% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,176.69, down 1.01% on the day, amid a bullish technical outlook and strong fundamental performance. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $8.38 surpassing the $6.40 consensus. Revenue surged to $65.18B in 2025, driving a net income margin of 33.53%. Recent news highlights promising pipeline developments in weight-loss and diabetes drugs, reinforcing growth prospects.
The outlook remains positive given robust revenue growth, high profitability, and analyst consensus favoring buys. Key risks include elevated valuation multiples and competitive pressures in the pharmaceutical sector. With a consensus price target of $1,350, upside potential exists, but investors should weigh execution risks against the company's innovation pipeline.
Petrobras (PBR) trades at $25.41, up 5.92% in 24 hours, reflecting strong momentum. The stock shows robust fundamentals with a P/E of 6.24 and net income margin of 24.52%, supported by recent earnings beats. Technical indicators signal a bullish trend, though RSI levels suggest potential overbought conditions. Positive news includes a new oil discovery off Amapa and a 22-year LNG deal with Cheniere Energy, highlighting growth prospects.
The outlook for PBR is favorable due to solid profitability, expansion projects, and analyst consensus leaning buy. Key risks involve political interference in Brazil, volatile oil prices, and high debt levels. Investors should weigh strong cash flows against geopolitical and commodity cycle exposures for balanced decision-making.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Petróleo Brasileiro SA
Petróleo Brasileiro S.A., commonly known as Petrobras, is a state-controlled Brazilian multinational corporation in the oil and gas industry. The company is one of the world's largest producers of oil and gas, primarily operating in exploration, production, refining, and power generation. Petrobras is particularly known for its deep-sea and ultra-deep-sea exploration and production activities in the vast pre-salt offshore reserves, which are a major component of Brazil's economy.
Read more on PBR →
